MedTrace Logo

The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)

NCT00964236 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-01-04

No results posted yet for this study

Summary

The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.

Conditions

Interventions

DRUG

Sapropterin

Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.

Sponsors & Collaborators

Principal Investigators

  • Shawn E Christ, Ph.D. · University of Missouri-Columbia

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964236 on ClinicalTrials.gov